USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
27 Jan 2022 | 03:45 PM GMT
Past Meeting

Companion DTx in Oncology: Opportunities for pharma

Participants:

Alexander Klein Founder & CEONedicareHealth System & Providers
Health System & Providers
Alexander Klein
Founder & CEONedicare
Myles Furnace Chief Commercial OfficerEolas MedicalStartup
Startup
Myles Furnace
Chief Commercial OfficerEolas Medical
Anish Shindore Founder & Managing PartnerGSD HealthHealth Tech & Solutions
Health Tech & Solutions
Anish Shindore
Founder & Managing PartnerGSD Health
Brian Flatley VP Consulting Services & US Pharma SolutionsS3 Connected HealthProfessional Services
Professional Services
Brian Flatley
VP Consulting Services & US Pharma SolutionsS3 Connected Health
Chris Wasden Chief Strategy OfficerTwillOther
Other
Chris Wasden
Chief Strategy OfficerTwill
Gandolf Finke CEOSynagenOther
Other
Gandolf Finke
CEOSynagen
Jin Lee Director of Digital HealthAstellas Pharma, IncOther
Other
Jin Lee
Director of Digital HealthAstellas Pharma, Inc
Jyri Yli-Villamo Head of Pharma Global Strategic PartnershipsKaiku Health
Jyri Yli-Villamo
Head of Pharma Global Strategic PartnershipsKaiku Health
Maike Schmitz Oncology LeadRoX Health GmbH
Maike Schmitz
Oncology LeadRoX Health GmbH
Matt Norton VP of Marketing & Commercial DevelopmentS3 Connected HealthProfessional Services
Professional Services
Matt Norton
VP of Marketing & Commercial DevelopmentS3 Connected Health
Smit Patel Partnership & Commercial GTM ExecutiveCVS HealthPayer & Insurer
Payer & Insurer
Smit Patel
Partnership & Commercial GTM ExecutiveCVS Health
Tahir Hussain Global Pharma Business Dev. Digital HealthBiofourmisOther
Other
Tahir Hussain
Global Pharma Business Dev. Digital HealthBiofourmis

About this Meeting

DTx solutions as digital drug companions are starting to show promise as valuable routes for market differentiation. There is more and more interest in drug-device combination products, propelled by COVID-19 and increased investment in DTx solutions in general. 

 Oncology treatments usually lead to adverse effects that compromise patients quality of life, hence it seems that the opportunity for DTx is particularly great in this therapeutic area. Join the meeting to discuss the following: 

  •  How can pharma leverage DTx to improve patients’ experience with their drugs? What is the ROI for pharma?  
  •  When is the right moment to incorporate the DTx (during trials, promotion, or other)? Can drug-DTx combo in oncology ease the market access process of the drug?
  • Beyond financial reasons, what are the main drivers for pharma to incorporate digital health solutions in the care plans of their oncological drugs?
  •  How to choose the right companion for a specific drug?  
  •  We have seen promising partnerships being formed in the last few years, such as, for instance, the collaboration between Voluntis and AstraZeneca as well as BMS, and Kaiku Health teaming up with Novartis and Roche. What are the results and key learnings of these partnerships so far?

About Us

HLTH Inc. is a dynamic community delivering unique value to the healthcare industry through a mix of unparalleled global events, inspirational content, and impact-driven initiatives.

USA Event Dates

  • 2026 | HLTH: Nov 15 – 18 | Las Vegas, NV | Register | Sponsor
  • 2027 | ViVE: Mar 14 – 17 | Nashville, TN | Be First to Know | Sponsor
  • 2027 | HLTH: Oct 17 – 20 | Las Vegas, NV
  • 2028 | HLTH: Nov 12 – 15 | Las Vegas, NV

Europe Event Dates

  • 2027 | HLTH Europe: Jun 21 – 24 | Amsterdam | Sponsor
  • 2028 | HLTH Europe: Jun 19 – 22 | Amsterdam

Important Notice on Hotel Scams

Any communication that claims to represent HLTH or any third party offering discounted hotel rooms or attendee lists is NOT AFFILIATED with HLTH and should be considered fraudulent. Please book your accommodations only through HLTH’s official channels to ensure authenticity and security.

© 2026 HLTH, INC. by Hyve Group - All Rights Reserved

About usPrivacy Policy Contact us